{
    "clinical_study": {
        "@rank": "28582", 
        "acronym": "RHACE 1", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 8 weeks"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 6, 8 or 12 weeks"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 4 weeks"
            }, 
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 8 weeks"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 6, 8 or 12 weeks"
            }, 
            {
                "arm_group_label": "Arm C", 
                "arm_group_type": "Experimental", 
                "description": "Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether treatment with\n      Daclatasvir/Asunaprevir/BMS-791325, with or without ribavirin, for 8, 6, or 4 weeks is\n      feasible for the treatment of genotype 1a chronic hepatitis C in patients without cirrhosis."
        }, 
        "brief_title": "Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus", 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects chronically infected with HCV genotype 1a\n\n          -  HCV RNA \u2265 10,000 IU/mL at screening\n\n          -  Treatment-na\u00efve subjects with no previous exposure to an interferon formulation (ie,\n             IFN\u03b1, pegIFN\u03b1), ribavirin (RBV), or HCV direct acting antiviral (DAA; protease,\n             polymerase inhibitor, etc.)\n\n        Exclusion Criteria:\n\n          -  Evidence of cirrhosis\n\n          -  Liver or any other organ transplant\n\n          -  Current or known history of cancer within 5 years prior to enrollment\n\n          -  Documented or suspected hepatocellular carcinoma (HCC)\n\n          -  Not eligible for sofosbuvir + pegylated interferon + ribavirin therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02098616", 
            "org_study_id": "IRB #1285", 
            "secondary_id": "AI443-128"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2", 
                    "Arm 3"
                ], 
                "description": "Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day", 
                "intervention_name": "DCV/ASV/BMS-791325", 
                "intervention_type": "Drug", 
                "other_name": "Fixed Dose Combination (FDC) of Daclatasvir/Asunaprevir/BMS-791325"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B", 
                    "Arm C"
                ], 
                "description": "Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day", 
                "intervention_name": "DCV/ASV/BMS-791325 + RBV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatitis", 
            "Hepatitis, Chronic", 
            "Hepatitis C", 
            "Hepatitis C, Chronic", 
            "Liver Diseases", 
            "Digestive System Diseases", 
            "Hepatitis, Viral, Human", 
            "RNA Virus Infections", 
            "Antiviral Agents", 
            "Drug Resistance, Viral"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "contact": {
                "email": "gregory.botwin@va.gov", 
                "last_name": "Gregory J. Botwin", 
                "phone": "562-826-5933"
            }, 
            "facility": {
                "address": {
                    "city": "Long Beach", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90822"
                }, 
                "name": "VA Long Beach Healthcare System"
            }, 
            "investigator": {
                "last_name": "Timothy R. Morgan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "RHACE 1: Rapid HepAtitis C Elimination Trial - A Pilot Evaluation of Twice Daily Fixed Dose Combination Asunaprevir +Daclatasvir + BMS-791325 \u00b1 Weight Based Ribavirin in Treatment-Na\u00efve, Non-cirrhotic Patients With Chronic Genotype 1a Hepatitis-C for Eight, Six or Four Weeks", 
        "overall_contact": {
            "email": "gregory.botwin@va.gov", 
            "last_name": "Gregory Botwin", 
            "phone": "562-826-5933"
        }, 
        "overall_official": {
            "affiliation": "VA Long Beach Healthcare System/Southern California Institute for Research and Education", 
            "last_name": "Timothy R. Morgan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United States: Federal Government"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of treated subjects in each enrolled arm with sustained virologic response (SVR)12. SVR12 is defined as HCV RNA < lower limit of quantification (LLOQ) target detected or target not detected (TD/TND) at post treatment Week 12", 
            "measure": "Sustained Virologic Response", 
            "safety_issue": "No", 
            "time_frame": "Post treatment week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02098616"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Southern California Institute for Research and Education", 
            "investigator_full_name": "Timothy Morgan, MD", 
            "investigator_title": "Chief, Hepatology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "On treatment safety, as measured by frequency of serious adverse events (SAEs) and adverse events (AEs), discontinuations due to AEs, and rates and grades of select laboratory abnormalities including liver function tests and hematology laboratory abnormalities in each arm", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Up to end of treatment (+7 days)"
            }, 
            {
                "description": "Proportion of treated subjects in each arm with SVR2, SVR4 and SVR 24, defined as HCV RNA < lower limit of quantification (LLOQ) target detected or target not detected (TD/TND) at post treatment Weeks, 2, 4, and 24 respectively", 
                "measure": "Sustained virologic response", 
                "safety_issue": "No", 
                "time_frame": "2, 4 and 24 weeks post-treatment"
            }, 
            {
                "description": "To assess the proportion of subjects who achieve sustained virologic response (SVR) 2, SVR4 and SVR24.", 
                "measure": "Post treatment virologic response", 
                "safety_issue": "No", 
                "time_frame": "post treatment Weeks 2 (SVR2), 4 (SVR4), and 24 (SVR24)"
            }, 
            {
                "description": "To assess antiviral activity, as measured by the proportion of subjects who achieve HCV RNA <lower limit of detection (LLOD) and/or < lower limit of quantification (LLOQ) at each on treatment visit.", 
                "measure": "On treatment virologic response", 
                "safety_issue": "No", 
                "time_frame": "On-treatment Day 2 and Weeks 1, 2, 4, 6, 8 and 12"
            }, 
            {
                "description": "To assess the proportion of subjects with virologic failure (including on treatment virologic breakthrough and relapse) and evaluate the emergence of viral resistant mutations.", 
                "measure": "Virologic failure", 
                "safety_issue": "No", 
                "time_frame": "On-treatment Day 2 and Weeks 1, 2, 4, 6, 8 and 12 and Post Treatment Weeks 2, 4, 12 and 24"
            }, 
            {
                "description": "To assess the predictive value of Day 2 virologic response on sustained virologic response (SVR) 12", 
                "measure": "Day 2 positive predictive value", 
                "safety_issue": "No", 
                "time_frame": "Post treatment Week 12"
            }, 
            {
                "description": "To compare the virologic response of subjects by genotype for interferon (IFN) lambda variants [' IL28B' and IFNL4-\u0394G]", 
                "measure": "Interferon lambda genotype and virologic response", 
                "safety_issue": "No", 
                "time_frame": "On-treatment Day 2 and Weeks 1, 2, 4, 6, 8 and 12 and Post Treatment Weeks 2, 4, 12 and 24"
            }
        ], 
        "source": "Southern California Institute for Research and Education", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "VA Long Beach Healthcare System", 
                    "agency_class": "U.S. Fed"
                }, 
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Bristol-Myers Squibb", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Timothy Morgan, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}